| Bioactivity | TP-1287, a prodrug of Alvocidib (HY-10005), is an orally active CDK9 inhibitor[1]. |
| Invitro | TP-1287 通过 CDK9 介导的 RNA 聚合酶 II 抑制 MCL-1 的表达[1]。 |
| In Vivo | TP-1287 (2.5-15 mg/kg; oral) 抑制多发性骨髓瘤模型肿瘤生长[1]。TP-1287 比 Alvocidib (HY-10005) 在更宽的 pH 范围内具有高可溶性，并且在口服给药后，在体内有效代谢为母体化合物[2]。 Animal Model: |
| Name | TP-1287 |
| CAS | 2044686-42-0 |
| Formula | C21H21ClNO8P |
| Molar Mass | 481.82 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tyagi E, et al. The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma. Blood, 2018, 132: 3269. [2]. Kim W, et al. TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib. Cancer Research, 2017, 77(13_Supplement): 5133-5133. |